Across randomized clinical trials and HF-focused cohorts, SGLT2 inhibitors have demonstrated modest and consistent changes in serum lipids, typically consisting of small increases in LDL-C and HDL-C and mild reductions in triglycerides [12-14]. This evidence concerns the gene SLC5A2 and hydrops fetalis.